A sympathetic view of human obesity

Clinical Autonomic Research

Volumn 23, Issue 1, 2013, Pages 9-14

  Lambert, Elisabeth A ^a,b   Straznicky, Nora E ^a   Lambert, Gavin W ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Human obesity; Sympathetic nerve activity

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; FATTY ACID; GLUCOSE; LEPTIN; MOXONIDINE;

ADRENERGIC SYSTEM; BLOOD FLOW VELOCITY; BODY WEIGHT; CALORIC RESTRICTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENERGY BALANCE; ENERGY EXPENDITURE; ESSENTIAL HYPERTENSION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERINSULINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY INJURY; LOW CALORY DIET; MENTAL STRESS; METABOLIC SYNDROME X; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; NORADRENALIN BLOOD LEVEL; OBESITY; PRESSORECEPTOR REFLEX; RECEPTOR DOWN REGULATION; REVIEW; RISK; SKELETAL MUSCLE; SYMPATHETIC REFLEX; SYMPATHETIC TONE; THERMOGENESIS; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; HUMANS; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84873083823     PISSN: 09599851     EISSN: 16191560     Source Type: Journal    
DOI: 10.1007/s10286-012-0169-3     Document Type: Review

References (33)

1. Alvarez GE, Ballard TP, Beske SD, Davy KP (2004) Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol 287:H414-H418
2. Bender R, Jockel KH, Trautner C, Spraul M, Berger M (1999) Effect of age on excess mortality in obesity. JAMA 281:1498-1504
3. Bray GA, York DA (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59:719-809
4. DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77:75-197
5. Dixon JB, Dixon ME (2006) Combined strategies in the management of obesity. Asia Pac J Clin Nutr 15(Suppl):63-69
6. Fenton C, Keating GM, Lyseng-Williamson KA (2006) Moxonidine: a review of its use in essential hypertension. Drugs 66:477-496
7. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M, Mancia G (2005) Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46:321-325
8. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G (1995) Sympathetic activation in obese normotensive subjects. Hypertension 25:560-563
9. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K (1990) The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. JAMA 264:354-358
10. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM (1967) The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med 67:48-59
11. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, Herzog H, Zukowska Z (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13:803-811
12. Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, Lambert G (2010) Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens 28:543-550
13. Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M, Lambert G (2010) Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 56:351-358
14. Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E, Lambert G (2007) Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 50:862-868
15. Lambert EA, Schlaich MP, Dawood T, Sari C, Chopra R, Barton DA, Kaye DM, Elam M, Esler MD, Lambert GW (2011) Single-unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover. J Physiol 589:2597-2605
16. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP (2010) Sympathetic nervous activation in obesity and the metabolic syndrome - causes, consequences and therapeutic implications. Pharmacol Ther 126:159-172
17. Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK (2011) Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond) 35:1395-1403
18. Logue J, Murray HM, Welsh P, Shepherd J, Packard C, Macfarlane P, Cobbe S, Ford I, Sattar N (2011) Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart 97:564-568
19. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML (2003) Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42:474-480
20. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD (2003) Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108:560-565
21. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932-934
22. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW (2009) Sympathetic activation in chronic renal failure. J Am Soc Nephrol 20:933-939
23. Straznicky NE, Eikelis N, Lambert EA, Esler MD (2008) Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 10:440-447
24. Straznicky NE, Eikelis N, Nestel PJ, Dixon JB, Dawood T, Grima MT, Sari CI, Schlaich MP, Esler MD, Tilbrook AJ, Lambert GW, Lambert EA (2012) Baseline sympathetic nervous system activity predicts dietary weight loss in obese metabolic syndrome subjects. J Clin Endocrinol Metab 97:605-613
25. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ (2005) Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 90:5998-6005
26. Straznicky NE, Lambert GW, Masuo K, Dawood T, Eikelis N, Nestel PJ, McGrane MT, Mariani JA, Socratous F, Chopra R, Esler MD, Schlaich MP, Lambert EA (2009) Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am J Clin Nutr 89:27-36
27. Straznicky NE, Lambert GW, McGrane MT, Masuo K, Dawood T, Nestel PJ, Eikelis N, Schlaich MP, Esler MD, Socratous F, Chopra R, Lambert EA (2009) Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes 58:1126-1132
28. Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R (2006) The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 6:343-348
29. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M (1997) Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96:3423-3429
30. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U (1994) Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 93:2365-2371
31. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE (2001) Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 14:694-698
32. Young JB, Macdonald IA (1992) Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 16:959-967
33. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA (2008) Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 37:663-684 ix